The effect and mechanism of ANXA1 on TPF chemosensitivity in oral squamous cell carcinoma

doi:10.19439/j.sjos.2019.03.001

Abstract

Abstract: PURPOSE: To investigate the mechanism of ANXA1 in TPF chemotherapy of oral squamous cell carcinoma (OSCC). Methods: ANXA1 overexpression and low-expression cell lines were constructed. The role of ANXA1 in TPF chemotherapy was analyzed by cell proliferation, cytotoxicity test, real-time PCR and Western blot, and the mechanism of ANXA1 in TPF chemotherapy through EMT (epithelial-mesenchymal transition) pathway was discussed. The data were analyzed with SPSS 18.0 software package. Results: After overexpression of ANXA1, cell growth rate decreased, cell cycle slowed down, sensitivity to TPF-induced drugs decreased, and EMT occurred in OSCC. After underexpression of ANXA1, cell growth rate increased, cell cycle accelerated, sensitivity to TPF chemotherapeutic drugs increased, and reverse EMT occurred in OSCC. Conclusions: In TPF chemotherapy of OSCC, overexpression of ANXA1 results in EMT of cells, which leads to decreased chemosensitivity.

Key words: Oral squamous cell carcinoma, ANXA1, EMT, Chemosensitivity

CLC Number:

R739.8

ZHU Dong-wang, SUN Wen-wen, ZHAO Tong-chao, ZHONG Lai-ping, ZHANG Zhi-yuan. The effect and mechanism of ANXA1 on TPF chemosensitivity in oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2019, 28(3): 225-230.

References

[1] Kademani D.Oral cancer[J]. Mayo Clin Proc, 2007, 82(7): 878-887.
[2] Petersen PE.The World Oral Health Report 2003: continuous improvement of oral health in the 21st century-the approach of WHO Global Oral Programme[J]. Community Dent Oral Epidemiol, 2003, 31(Suppl 1): 3-23.
[3] Neville BW, Day TA.Oral cancer and precancerous lesions[J]. CA Cancer J Clin, 2002, 52(4): 195-215.
[4] Parkin DM, Bray F, Ferlay J, et al.Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
[5] Zhong L, Zhang C, Ren G, et al.Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma[J]. Oncotarget, 2015, 6(21): 18707-18714.
[6] Zhu DW, Liu Y, Yang X, et al.Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade[J]. BMC Cancer, 2013, 13: 301.
[7] Faria PC, Sena AA, Nascimento R, et al.Expression of annexin A1 mRNA in peripheral blood from oral squamous cell carcinoma patients[J]. Oral Oncol, 2010, 46(1): 25-30.
[8] Wang LP, Bi J, Yao C, et al.Annexin A1 expression and its prognostic significance in human breast cancer[J]. Neoplasma, 2010, 57(3): 253-259.
[9] de Graauw M, van Miltenburg MH, Schmidt MK, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells[J]. Proc Natl Acad Sci USA, 2010, 107(14): 6340-6345.
[10] Maschler S, Gebeshuber CA, Wiedemann EM, et al.Annexin A1 attenuates EMT and metastatic potential in breast cancer[J]. EMBO Mol Med, 2010, 2(10): 401-414.
[11] Fischer KR, Durrans A, Lee S, et al.EMT is not required for lung metastasis but contributes to chemoresistance[J]. Nature, 2015, 527(7579): 472-476.
[12] Zheng X, Carstens JL, Kim J, et al.Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer[J]. Nature, 2015, 527(7579): 525-530.
[13] Guo C, Liu S, Sun MZ.Potential role of Anxa1 in cancer[J]. Future Oncol, 2013, 9(11): 1773-1793.
[14] Li S, Zhang XM, Zhang RK, et al.Hippo pathway contributes to cisplatin resistant-induced EMT in nasopharyngeal carcinoma cells[J]. Cell Cycle, 2017, 16(17): 1601-1610.

[1]	DONG Lin-sheng, TANG Jin, CHENG Wei, RAN Jing-xuan, LIU Zhao-bo, LI Ya-dong. Expression and prognostic value of IL-6 and β-catenin in oral squamous cell carcinoma [J]. Shanghai Journal of Stomatology, 2023, 32(3): 280-286.
[2]	HU Xiao-yuan, WANG Ning, ZHANG Xiao-ye, YANG Qian, GAO Fei, WANG Cheng-qin, SHANG Wei, XIANG Feng-gang, FENG Yuan-yong. Chemerin mediated neutrophil infiltration in oral squamous cell carcinoma and predicted poor prognosis [J]. Shanghai Journal of Stomatology, 2023, 32(2): 158-165.
[3]	GUO Meng-yao, LI Kai-yu, NIE Min-hai, LIU Xu-qian. Effect of up-regulation of Decorin on expression of EGFR, C-Myc and p21 in nude mice with oral squamous cell carcinoma [J]. Shanghai Journal of Stomatology, 2023, 32(1): 40-46.
[4]	QIAN Yi, DENG Chao, XU Xiao-bo, CHEN Ye-jun, HU Yun-ping, HONG Li-lin, FENG Da-jun. Clinical analysis of immune function, intestinal flora changes in patients with oral squamous carcinoma before, after treatment [J]. Shanghai Journal of Stomatology, 2022, 31(5): 523-529.
[5]	WEN Xu-tao, MA Zhen, ZHANG Chong, Tao Shi-cheng, CHEN Xing-jin, MAI Hua-ming. Maintenance of the stemness in CD133⁺ primary oral squamous cell carcinoma cells under different culture conditions [J]. Shanghai Journal of Stomatology, 2022, 31(4): 343-348.
[6]	QIN Zhi-ming, JIE Wei-ping, CHI Yan-ting, LI Hong-feng, LI Bin-bin. Preliminary establishment of an unsupervised quantification model of Ki-67 proliferation index based on local variable threshold method [J]. Shanghai Journal of Stomatology, 2022, 31(3): 248-254.
[7]	CHEN Juan, CAO Ruo-yan, LIU Yang, HONG Peng-yu, TANG Zhan-gui. Expression of TNFAIP6 in oral verrucous carcinoma and oral squamous cell carcinoma and its relationship with clinicopathology [J]. Shanghai Journal of Stomatology, 2022, 31(2): 167-172.
[8]	MAIERHABA·Maihemuti, BAI Jie, RUSITANMU·Yimiti, YAO Zhi-tao. Influencing factors of nutritional status and change in 50 patients with oral squamous cell carcinoma during treatment [J]. Shanghai Journal of Stomatology, 2022, 31(2): 205-210.
[9]	TAN Yi-ran, ZHAO Tong-chao, JU Wu-tong, ZHONG Lai-ping. Experimental investigation of vincristine on chemosensitivity through Stathmin regulation in oral squamous cell carcinoma [J]. Shanghai Journal of Stomatology, 2022, 31(1): 1-5.
[10]	XIE Fei, QIN Xing, TONG Tong, JIANG Ying-ying, ZHANG Jian-jun. Insight into the role of IGF2BP1 in drug resistant mechanism of oral squamous cell carcinoma [J]. Shanghai Journal of Stomatology, 2021, 30(5): 456-461.
[11]	LI Lei, LI Xiao-dong, ZHUANG Qian-wei, GE Liang-yu, LI Zhi-ping, GU Qian-ping, BAI Yu-ting, MENG Jian. Analysis of curative effect of ultrasonic hyperthermia combined with TPF chemotherapy on 19 elderly with advanced oral squamous cell carcinoma [J]. Shanghai Journal of Stomatology, 2021, 30(5): 543-547.
[12]	SHAO Xiao-jun, ZHU Qiao, LIU You, HAN Xiao-dong, LIN Xiao-zhen, XI Qing. Correlation of betel nut chewing and clinicopathologic factors of oral squamous cell carcinoma [J]. Shanghai Journal of Stomatology, 2021, 30(3): 268-272.
[13]	JIN Neng-hao, NAN Xin-rong, YAN Xing-quan. Expression and clinical significance of BTG-1 in 78 patients with oral squamous cell carcinoma [J]. Shanghai Journal of Stomatology, 2021, 30(2): 140-144.
[14]	XUE Jia-yi, ZHU Xiao-yan, WEI Chang-lei, SUN Pei, ZHANG Hui, DENG Jing. Study of salivary metabonomics in patients with oral squamous cell carcinoma and leukoplakia [J]. Shanghai Journal of Stomatology, 2021, 30(2): 201-205.
[15]	WANG Ke, PENG Guo-guang, TAN Yu-lian, HE Shan-zhi, LUO Cui-fen. MiR-99a inhibits proliferation of oral squamous cell carcinoma by targeting mTOR pathway [J]. Shanghai Journal of Stomatology, 2021, 30(1): 44-49.